Claudio D. Gonzalez, Jorge Alvariñas, Maria F.G. Bagnes and Guillermo Di Girolamo* Pages 54-60 (7)
Methods: A comprehensive literature search was carried out to identify eligible studies from MEDLINE/PubMed, EMBASE and SCIELO databases through 1995 first semester.
Results: Several factors limit the effect of metformin on embryos. In contrast, placental transport of metformin is effective allowing for a higher fetal exposure; the impact of this finding remains unclear. It seems that the interruption of metformin after a pregnancy diagnosis in women with PCOS is not associated with a higher miscarriage risk and it continuation does not seem to impair the maternal metabolic prognosis or prevent emerging GDM.
Conclusions: It seems to have no sense to prolong the use of metformin after a pregnancy diagnosis in women with PCOS. Patients with GDM may be treated with metformin under on judicious basis, and a careful attachment to clinical guidelines and regulations is recommended. The long-term effects of pre-natal exposure to metformin on the offspring remain uncertain.
Metformin, gestational diabetes mellitus, polycystic ovary syndrome, pregnancy outcomes, hypertension, preeclampsia.
Universidad de Buenos Aires, Facultad de Medicina, Centro de Vigilancia y Seguridad de Medicamentos, Departamento de Toxicologia y Farmacologia, Buenos Aires, Sociedad Argentina de Diabetes, Comite de Farmacologia, Buenos Aires, Departamento de Farmacologia, Instituto Universitario CEMIC, Buenos Aires, Universidad de Buenos Aires, Facultad de Medicina, Centro de Vigilancia y Seguridad de Medicamentos, Departamento de Toxicologia y Farmacologia, Buenos Aires